Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Trial of Vemurafenib Plus Copanlisib to Enhance Radioiodine Avidity in Radioiodine-Refractory Thyroid Cancers

NCT04462471 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT04462471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04462471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Trial of Vemurafenib Plus Copanlisib to Enhance Radioiodine Avidity in Radioiodine-Refractory Thyroid Cancers
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
June 26, 2020
Completion date
September 29, 2023
Enrollment
8 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

braf v600e mutation positive, thyroid cancer, thyroid cancer (follicular cell), thyroid cancer, follicular, thyroid cancer, papillary, thyroid carcinoma